Down Near Its 5-Year Low, Is Novo Nordisk Stock Too Cheap to Pass Up?

Key Points
Novo Nordisk unveiled a troubling guidance for 2026, which tanked the stock.
It recently reached a deal with telehealth company Hims & Hers Health to sell its GLP-1 products.
The stock is trading at just 10 times its earnings.
- 10 stocks we like better than Novo Nordisk ›
Shares of Danish drugmaker Novo Nordisk (NYSE: NVO) have been in a full-blown tailspin over the past 12 months. The stock has lost more than half of its value as the company has been delivering some underwhelming results recently, and its guidance isn't looking too promising, either.
It's been a bit of a perfect storm that has resulted in Novo Nordisk stock now tumbling to levels it hasn't been at since early 2021. That's even before its weight loss drug, Wegovy, obtained approval from regulators, which was in the summer of that year.
Will AI create the world's first trillionaire? Our team just released a report on the one little-known company, called an "Indispensable Monopoly" providing the critical technology Nvidia and Intel both need. Continue »
To say investors have been bearish on Novo Nordisk would be an understatement. But the big question is, has the bearishness become excessive, and has the healthcare stock become so cheap that it's effectively become a no-brainer buy?
Novo Nordisk may be down, but I wouldn't count it out
It's a tough road ahead for Novo Nordisk as the company has a new CEO, and it slashed its guidance for the year ahead. It projects that its revenue could be down by as much as 13% for the current year, even as it has launched a new Wegovy pill.
The company is facing pricing pressure, but management believes that by lowering prices, winning over customers, and gaining market share, it could set itself up for better growth in the future. Novo Nordisk has also reached a deal with telehealth company Hims & Hers Health recently to sell its GLP-1 products on Hims' platform, which could help grow sales even further. That announcement came after Novo's troubling guidance, and thus, may result in better growth numbers than feared.
The stock is a steal, even if you're concerned about its growth prospects
The market has a tendency to overprice stocks that are doing well and undervalue ones that are struggling. But that can be good news for long-term investors, because it allows you to lock in a low price for a company that is underperforming. Billionaire investor Warren Buffett has said in the past that he likes to invest in businesses that are in "temporary trouble" simply because it can be highly advantageous to do so, particularly when the market is undervaluing them.
In Novo Nordisk's case, I think the business is facing temporary headwinds, and that it's still a solid company to invest in for the long haul. The stock today trades just 10 times its earnings, which is a dirt cheap multiple for one of the top healthcare companies in the world. At this kind of valuation, you're getting an excellent margin of safety with the investment, and there could be significant upside in the future.
Novo Nordisk may be in the midst of a challenging year, but as long as you're willing to stay the course and remain invested for the long term, it can be an excellent buy right now.
Should you buy stock in Novo Nordisk right now?
Before you buy stock in Novo Nordisk, consider this:
The Motley Fool Stock Advisor analyst team just identified what they believe are the 10 best stocks for investors to buy now… and Novo Nordisk wasn’t one of them. The 10 stocks that made the cut could produce monster returns in the coming years.
Consider when Netflix made this list on December 17, 2004... if you invested $1,000 at the time of our recommendation, you’d have $494,747!* Or when Nvidia made this list on April 15, 2005... if you invested $1,000 at the time of our recommendation, you’d have $1,094,668!*
Now, it’s worth noting Stock Advisor’s total average return is 911% — a market-crushing outperformance compared to 186% for the S&P 500. Don't miss the latest top 10 list, available with Stock Advisor, and join an investing community built by individual investors for individual investors.
*Stock Advisor returns as of March 20, 2026.
David Jagielski, CPA has positions in Novo Nordisk. The Motley Fool has positions in and recommends Hims & Hers Health. The Motley Fool recommends Novo Nordisk. The Motley Fool has a disclosure policy.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.